Incyte - 28 Year Stock Price History | INCY

Historical daily share price chart and data for Incyte since 1993 adjusted for splits. The latest closing stock price for Incyte as of October 27, 2021 is 64.97.
  • The all-time high Incyte stock closing price was 152.66 on March 15, 2017.
  • The Incyte 52-week high stock price is 101.47, which is 56.2% above the current share price.
  • The Incyte 52-week low stock price is 64.08, which is 1.4% below the current share price.
  • The average Incyte stock price for the last 52 weeks is 80.82.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Incyte Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 80.0535 86.4500 100.5000 64.2200 64.9700 -25.30%
2020 88.8053 85.9700 109.6900 63.1800 86.9800 -0.39%
2019 81.9818 63.5600 95.7200 63.5600 87.3200 37.32%
2018 72.8748 100.8900 100.9800 58.5000 63.5900 -32.86%
2017 121.3776 102.3200 152.6600 93.5600 94.7100 -5.55%
2016 83.5442 103.3200 108.1000 63.0500 100.2700 -7.54%
2015 102.6879 73.7600 131.4700 71.4900 108.4500 48.34%
2014 57.1143 51.2300 78.8900 43.1000 73.1100 44.40%
2013 28.9761 17.0000 51.3400 17.0000 50.6300 204.82%
2012 19.2983 14.9900 25.8400 14.7800 16.6100 10.66%
2011 15.7089 16.5200 20.7600 11.7800 15.0100 -9.36%
2010 13.4671 9.5000 17.1700 9.4100 16.5600 81.78%
2009 4.7656 3.8500 9.4000 2.0500 9.1100 140.37%
2008 8.3997 9.9800 12.4200 2.4900 3.7900 -62.29%
2007 7.1488 6.0200 10.7800 4.8100 10.0500 72.09%
2006 4.8336 5.3400 6.2000 3.5800 5.8400 9.36%
2005 7.1163 9.6400 9.6600 4.2700 5.3400 -46.55%
2004 8.3024 6.8200 10.9600 5.4500 9.9900 46.05%
2003 4.6660 4.9090 6.9100 2.6700 6.8400 50.00%
2002 8.0137 19.4000 19.6900 2.9800 4.5600 -76.54%
2001 18.1810 22.5600 30.6300 10.7600 19.4400 -21.86%
2000 47.9850 44.8150 140.2500 23.5600 24.8800 -17.07%
1999 12.9288 18.5000 31.5650 8.2800 30.0000 60.51%
1998 17.8036 21.3750 25.1900 9.2500 18.6900 -16.93%
1997 16.6527 12.7500 22.5000 10.6250 22.5000 74.76%
1996 9.2842 7.0300 12.8750 6.1250 12.8750 106.00%
1995 4.4132 3.4075 6.2500 3.2825 6.2500 80.12%
1994 2.4212 2.1875 3.9075 1.7188 3.4700 54.22%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.697B $2.667B
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86